No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen
- 21 September 2014
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 148 (1) , 135-142
Abstract
Tamoxifen is an effective endocrine treatment for early breast cancer (EBC) but increases the risk of venous thromboembolism. Whether Asian EBC patients (pts) bear the same risk when treated with adjuvant tamoxifen is uncertain. EBC pts diagnosed between 2004 and 2009 were selected from a population database in Taiwan. The pts were followed up from the index date to December 31, 2011 to collect events of deep vein thrombosis (DVT) and pulmonary embolism (PE). Cumulative incidence rates and hazard ratios (HRs) were used to compare the risk between pts treated with and without tamoxifen. In addition, comorbidities were included in an adjusted model of the risk of DVT and PE. A total of 28,029 EBC pts, including 17,843 (63.8 %) in the tamoxifen group and 10,155 (36.2 %) in the nontamoxifen group, were analyzed. The 7-year cumulative incidence rates for DVT and PE were 2.58 and 0.32 % in the tamoxifen group and 2.51 and 0.32 % in the nontamoxifen group (P = 0.92 for DVT, P = 0. 65 for PE), respectively. The HR for the nonadjusted and adjusted models showed no differences in DVT and PE risks between the tamoxifen and nontamoxifen groups. The uterine cancer risk was significantly increased in the pts receiving tamoxifen (adjusted HR = 2.79, P < 0.001), suggesting tamoxifen compliance. The risks of developing DVT and PE are not increased in Asian EBC pts receiving adjuvant tamoxifen. Ethnicity differences should be considered when discussing optimal endocrine treatments with EBC pts.Keywords
This publication has 29 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for cliniciansBreast Cancer Research and Treatment, 2013
- The Impact of Diabetes Mellitus on Prognosis of Early Breast Cancer in AsiaThe Oncologist, 2012
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2011
- Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerNew England Journal of Medicine, 2009
- Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control StudyJournal of Clinical Oncology, 2008
- Tamoxifen and the Risk of Endometrial Cancer in Japanese Women with Breast CancerSurgery Today, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005